Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, has received another milestone payment from German pharmaceutical company Boehringer Ingelheim for the progress of a second oncology drug candidate discovered during the first phase of the partnership, into the clinic.
In this Phase 1 clinical trial, BI 765049, will be administered to patients with advanced solid tumours including colorectal cancer, gastric carcinoma, pancreatic carcinoma, non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinoma.
OBT’s Chief Executive Officer, Dr. Christian Rohlff, said: “The advancement of the second oncology drug candidate, developed under our collaboration with BI, into the clinic is a major validation of our proprietary OGAP® drug discovery platform.
“Selecting the right target is fundamental for the successful development of a first-in-class antibody drug product. OBT’s platforms are designed to discover and engineer antibody constructs to novel therapeutic targets to best address difficult-to-treat cancers.”
Oxford BioTherapeutics is a clinical stage oncology company; based in Oxford, UK; Morristown, New Jersey and San Jose, California, USA; with a pipeline of first-in-class immuno-oncology (IO) therapies specifically designed to fulfil major unmet patient needs in cancer therapeutics. These include bi-specific, Chimeric Antigen Receptor T Cell (CAR-T), Antibody Drug Conjugate (ADC)and Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) therapeutics.
OBT’s proprietary OGAP® target discovery platform comprises one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly-qualified oncology targets, of which three programs are in clinical development in the USA and Europe. OBT’s IO discovery process provides unique insights into the cancer-immune cell synapse and has identified several novel IO candidates for cancer therapies.